Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2013

View Archived Issues

Small-molecule antiviral agents target HIV-1 replication

AstraZeneca and Moderna Therapeutics to develop messenger RNA therapeutics

Bluebird bio enters collaboration with Celgene

H3 Biomedicine and BGI to develop and share cancer genomic sequencing data

Benefits demonstrated for onabotulinumtoxinA in patients with OAB

Novel QC inhibitor shows promise as AD therapy in a phase I trial

BioCryst Pharmaceuticals patents new tyrosine-protein kinase inhibitors

Acofide tablets approved in Japan for functional dyspepsia

Auxilium announces topline data from study of Xiaflex in frozen shoulder syndrome

TOP2A as an independent biomarker of NPC tumor aggressiveness

Inovelon approved in Japan for Lennox-Gastaut syndrome

Neuropore Therapeutics presents novel therapeutic candidate for neurological disorders

arGEN-X advances ARGX-112 into preclinical development

New agents for substance abuse and dependence divulged by Gilead Sciences

Shionogi receives approval for metreleptin in Japan

Shin Nippon Biomedical and Nagasaki University enter collaboration

Reversible covalent modification of KEAP1 as a promising approach for PD therapy

Onglyza approved in Japan for type 2 diabetes

BioCryst commences clinical study of candidate for hereditary angioedema

Lundbeck and Otsuka expand collaboration to include Lu-AE-58054

Shire gains lifitegrast with acquisition of SARcode Bioscience

Chugai gains Japanese approval for subcutaneous formulation of Actemra

Japanese authorities approve denosumab for osteoporosis

FDA approves botulism antitoxin manufactured by Cangene

GSK gives update on FDA's review of H5N1 adjuvanted influenza vaccine

Eisai set to launch neuromuscular-blocking agent in Japan for cervical dystonia

Bristol-Myers Squibb presents new series of anti-HIV agents

FDA approves Novartis' dry powder inhaled antibacterial Tobi Podhaler